Xinyao Biotechnology

Xinyao Biotechnology, originally founded as Xiniao Biotechnology, is a precision medicine platform company headquartered in Hangzhou, China, specializing in advanced spatial multi-omics and high-throughput single-cell sequencing. The company develops proprietary technologies, such as the Spatial-SOP (S-SOP) platform, which enable the mapping of gene expression within the structural context of biological tissues. Its services are primarily utilized by pharmaceutical companies and academic research institutions for drug target discovery, biomarker validation, and mechanistic studies in complex diseases. By integrating high-resolution molecular profiling with spatial architecture, Xinyao Biotechnology aims to provide deeper insights into cellular heterogeneity to accelerate the development of precision therapeutics. Since its inception in 2021, the company has secured significant investment from major venture capital firms to expand its bioinformatics capabilities and service portfolio.